Overview

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing 302 Hospital
Treatments:
Antibodies